Antibody Contract Manufacturing Market Report 2026

The antibody contract manufacturing market size has grown rapidly in recent years. It will grow from $16.79 billion in 2025 to $19.32 billion in 2026 at a compound annual growth rate (CAGR) of 15%. The growth in the historic period can be attributed to rising biologics development pipelines, increased outsourcing by biopharmaceutical companies, expansion of mammalian cell culture platforms, growing clinical trial activity for antibodies, availability of specialized cmo infrastructure.

The antibody contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $34.72 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to growing demand for commercial-scale antibody production, increasing investments in next-generation biologics, rising focus on cost-efficient manufacturing models, expansion of personalized medicine pipelines, increasing regulatory approvals for antibody therapies. Major trends in the forecast period include expansion of large-scale antibody manufacturing capacity, rising adoption of single-use bioprocessing systems, growing demand for bispecific antibodies and adcs, increased focus on flexible and scalable manufacturing models, enhanced emphasis on regulatory compliance and quality control.

The increasing number of clinical trials is expected to drive the growth of the antibody contract manufacturing market in the coming years. Clinical trials are research studies conducted with human participants to assess the safety and efficacy of new medical treatments, interventions, or diagnostic procedures. The growing number of clinical trials involving antibody-based therapeutics or diagnostics creates demand for high-quality antibodies, ensuring a timely and compliant supply for these studies. For example, in May 2023, according to ClinicalTrials.gov, a part of the National Institutes of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, across all 50 states of the United States and 221 countries, the number of registered clinical trials increased from 399,499 in 2022 to 437,533 in 2023. Moreover, approximately 241,498 studies, or 53% of the total, were registered outside the United States, compared to 140,492 studies (31%) registered within the United States. Consequently, the rising number of clinical trials is fueling the growth of the antibody contract manufacturing market.

Major companies operating in the antibody contract manufacturing market are emphasizing the development of innovations, such as single-use technology that reduces cross-contamination risks and lowers operational costs. Single-use technology (SUT) involves disposable components and systems utilized in biopharmaceutical manufacturing processes. For example, in September 2024, Merck & Co., a US-based pharmaceutical company, introduced the Mobius ADC Reactor aimed at improving the manufacturing of antibody-drug conjugates. This new single-use reactor, specifically developed for antibody-drug conjugate production, enhances manufacturing efficiency by 70% compared to conventional stainless steel or glass methods. Its single-use design decreases the risk of cross-contamination and reduces operational expenses, enabling faster turnaround times. Furthermore, advanced film technology strengthens the bag and enhances leak resistance, ensuring the safety of highly potent active pharmaceutical ingredients. This innovation helps biopharmaceutical companies produce essential therapies more safely and efficiently.

In September 2024, Agilent Technologies, a US-based provider of analytical and clinical laboratory technologies, instruments, software, services, and expertise, acquired BIOVECTRA for an undisclosed amount. Through this acquisition, Agilent seeks to strengthen its contract development and manufacturing capabilities, broaden its biologics and targeted therapeutics portfolio, and support advanced modalities, including gene editing. BIOVECTRA is a Canada-based provider of contract development and manufacturing services (CDMO) specializing in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.

Major companies operating in the antibody contract manufacturing market are Lonza Group AG, Catalent Inc, Samsung Biologics Co Ltd, Wuxi Biologics Cayman Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim BioXcellence, AGC Biologics, FUJIFILM Diosynth Biotechnologies, AbbVie Inc, Charles River Laboratories International Inc, mAbxience, KBI Biopharma Inc, Abzena Ltd, Just‑Evotec Biologics, Northway Biotech, Cerbios‑Pharma, Scorpius BioManufacturing, Lotte Biologics, Rentschler Biopharma SE, Cytiva (Life Sciences CDMO), Xcellon Biologics, Celonic AG, Syngene International Ltd.

North America was the largest region in the antibody contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibody contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the antibody contract manufacturing market by increasing costs of imported bioreactors, chromatography systems, filtration units, raw materials, and single-use consumables required for antibody production. Biopharmaceutical manufacturing hubs in North America and Europe are most affected due to reliance on globally sourced equipment and materials, while Asia-Pacific faces higher costs for export-oriented manufacturing services. These tariffs are increasing production expenses and contract pricing pressures. However, they are also encouraging localized biomanufacturing investments, regional supplier development, and expansion of domestic antibody manufacturing capabilities.

The antibody contract manufacturing market research report is one of a series of new reports that provides antibody contract manufacturing market statistics, including antibody contract manufacturing industry global market size, regional shares, competitors with a antibody contract manufacturing market share, detailed antibody contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the antibody contract manufacturing industry. This antibody contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antibody contract manufacturing involves outsourcing the production and creation of antibodies to specialized contract manufacturing organizations (CMOs). These CMOs possess the expertise, infrastructure, and resources required to produce antibodies on behalf of pharmaceutical and biotechnology companies.

The primary products of antibody contract manufacturing include monoclonal antibodies, polyclonal antibodies, and others. Monoclonal antibodies (mAbs) are antibodies specifically designed to target a particular antigen, and antibody contract manufacturing plays a crucial role in producing them on a large scale, ensuring consistent quality and quantity for therapeutic or diagnostic use. They are developed from sources such as mammals and microbes at preclinical, clinical, and commercial stages, and are utilized by end users including biopharmaceutical companies, research laboratories, and others.

The antibody contract manufacturing market includes revenues earned by entities by providing services such as cell line development, process optimization, and the manufacturing of clinical trial materials. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.